Integrating Molecular Profiles Into PV-Specific Treatment Planning
A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for polycythemia vera (PV), weighing factors such as symptom burden, risk stratification, and genetic markers to optimize therapeutic outcomes.
Video content above is prompted by the following:
- Please describe how this patient’s initial presentation and molecular profile informs your PV treatment approach.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
